{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:51:53Z","timestamp":1777607513884,"version":"3.51.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013274","name":"Institut National d\u2019Assurance Maladie-Invalidit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and objectives:<\/jats:bold> Biosimilar medicines have been on the European market for 15\u00a0years. Despite the extensive and positive experience with biosimilars across Europe, their uptake remains limited in Belgium. One of the possible factors limiting uptake in clinical practice is the inadequate understanding and lack of trust in biosimilars among patients. This study aimed to assess the level of knowledge and perceptions about biosimilar medicines among Belgian patients in the ambulatory care.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study consisted of online questionnaires among Belgian patients in the ambulatory care (i.e., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn\u2019s disease, ulcerative colitis, diabetes mellitus type I and II). The results were collected between December 2020 and February 2021. The data were analyzed with descriptive and inferential statistics.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 657 patients across all disease areas of interest participated in this study. Only 38% of patients had heard of biosimilars before. Of those patients, most (58%) were aware that biosimilars are as safe and effective as their reference product. The vast majority of respondents (68%) would agree with transitioning to a biosimilar if their physician prescribed it, only 3% would never agree with a transition to a biosimilar. If a physician would propose to change their current originator biological therapy with its biosimilar, nearly all patients (95%) want their physician to explain the decision and inform them. For additional information about biosimilars, Belgian patients prefer brochures or folders (41%), or available resources on the internet (35%). Physicians were indicated as the preferred source of information (95%), followed by pharmacists (51%), academia (39%), and patient associations (35%). Most patients require information regarding the safety and efficacy (78%), price and reimbursement (64%), and the clinical development process (56%) of the biosimilar.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Belgian patients require information about biosimilar medicines. However, most patients are open and positive towards transitioning their current biological therapy with its biosimilar if sufficiently supported by their healthcare providers.<\/jats:p>","DOI":"10.3389\/fphar.2021.789640","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T08:05:22Z","timestamp":1641369922000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care"],"prefix":"10.3389","volume":"12","author":[{"given":"Yannick","family":"Vandenplas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liese","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Simoens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Van Wilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold G.","family":"Vulto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40259-017-0238-1","article-title":"Patients' Understanding and Attitudes towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey","volume":"31","author":"Aladul","year":"2017","journal-title":"BioDrugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.20344\/amp.10127","article-title":"Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients","volume":"31","author":"Azevedo","year":"2018","journal-title":"Acta Med. Port."},{"key":"B3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40259-020-00452-9","article-title":"European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption","volume":"34","author":"Barbier","year":"","journal-title":"BioDrugs"},{"key":"B4","volume-title":"Effectively Educating Clinicians and Patients on Biosimilars across Europe: Getting the Right Message across","author":"Barbier","year":""},{"key":"B5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","article-title":"The Efficacy, Safety and Immunogenicity of Switching between Reference Biopharmaceuticals and Biosimilars: a Systematic Review","volume":"108","author":"Barbier","year":"","journal-title":"Clin. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40545-021-00330-x","article-title":"Knowledge and Perception of Biosimilars in Ambulatory Care: A Survey Among Belgian Community Pharmacists and Physicians","volume":"14","author":"Barbier","year":"","journal-title":"J. Pharm. Pol. Pract."},{"key":"B7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40259-020-00433-y","article-title":"The Importance of Countering Biosimilar Disparagement and Misinformation","volume":"34","author":"Cohen","year":"2020","journal-title":"BioDrugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40273-014-0163-9","article-title":"Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study","volume":"32","author":"Dylst","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"B9","volume-title":"Biosimilars in the EU: Information Guide for Healthcare Professionals","year":"2017"},{"key":"B10","volume-title":"Biologische en biosimilaire geneesmiddelen","year":"2018"},{"key":"B11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jbspin.2019.01.001","article-title":"Patients' Information and Perspectives on Biosimilars in Rheumatology: A French Nation-wide Survey","volume":"86","author":"Frantzen","year":"2019","journal-title":"Jt. Bone. Spine"},{"key":"B12","volume-title":"Patent Expiry Dates for Biologicals: 2018 Update","year":"2019"},{"key":"B13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00296-020-04576-7","article-title":"Patients' Beliefs and Behaviours Are Associated with Perceptions of Safety and Concerns in a Hypothetical Biosimilar Switch","volume":"41","author":"Gasteiger","year":"2020","journal-title":"Rheumatol. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-015-0132-7","article-title":"How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013","volume":"29","author":"Ingrasciotta","year":"2015","journal-title":"BioDrugs"},{"key":"B15","volume-title":"The Impact of Biosimilar Competition in Europe","year":"2020"},{"key":"B16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/PPA.S104891","article-title":"Patient Attitudes and Understanding about Biosimilars: An International Cross-Sectional Survey","volume":"10","author":"Jacobs","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"B17","volume-title":"Health Literacy : What Lessons Can Be Learned from the Experiences of Other Countries","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","article-title":"Nocebos in Rheumatology: Emerging Concepts and Their Implications for Clinical Practice","volume":"14","author":"Kravvariti","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","article-title":"Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent","volume":"32","author":"Kristensen","year":"2018","journal-title":"BioDrugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.18553\/jmcp.2019.25.1.102","article-title":"Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review","volume":"25","author":"Leonard","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B21","first-page":"1","volume-title":"KCE Report: Barri\u00e8res en drijfveren voor de opname van biosimilaire geneesmiddelen in Belgi\u00eb","author":"Lepage-Nefkens","year":"2013"},{"key":"B22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/ph14030283","article-title":"Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain","volume":"14","author":"Lobo","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/ph13100324","article-title":"Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany","volume":"13","author":"Moorkens","year":"","journal-title":"Pharmaceuticals (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fphar.2016.00193","article-title":"Overcoming Barriers to the Market Access of Biosimilars in the European union: The Case of Biosimilar Monoclonal Antibodies","volume":"7","author":"Moorkens","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40259-019-00345-6","article-title":"Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting","volume":"33","author":"Moorkens","year":"2019","journal-title":"BioDrugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/17843286.2020.1761690","article-title":"Biosimilars in Belgium: a Proposal for a More Competitive Market","volume":"76","author":"Moorkens","year":"","journal-title":"Acta Clin. Belg."},{"key":"B27","first-page":"280","article-title":"Biosimilars in Oncology - Part I: The Principles of Biosimilars","volume":"14","author":"Moorkens","year":"","journal-title":"Belgian J. Med. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/ecco-jcc\/jjw138","article-title":"Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations","volume":"11","author":"Peyrin-Biroulet","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/1744666X.2018.1512406","article-title":"The Nocebo Effect: a Clinical challenge in the Era of Biosimilars","volume":"14","author":"Pouillon","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1272308","DOI":"10.1080\/20016689.2016.1272308","article-title":"Key Drivers for Market Penetration of Biosimilars in Europe","volume":"5","author":"R\u00e9muzat","year":"2017","journal-title":"J. Mark Access Health Pol."},{"key":"B31","volume-title":"Onderwijsniveau van de Belgische bevolking","year":""},{"key":"B32","volume-title":"Structuur van de Belgische bevolking. Statbel","year":""},{"key":"B33","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/art.40516","article-title":"Open-Label, Non-mandatory Transitioning from Originator Etanercept to Biosimilar SB4: Six-Month Results from a Controlled Cohort Study","volume":"70","author":"Tweehuysen","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.40324","article-title":"Subjective Complaints as the Main Reason for Biosimilar Discontinuation after Open-Label Transition from Reference Infliximab to Biosimilar Infliximab","volume":"70","author":"Tweehuysen","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/10810730.2013.825668","article-title":"The Relationship between Health, Education, and Health Literacy: Results from the Dutch Adult Literacy and Life Skills Survey","volume":"18","author":"van der Heide","year":"2013","journal-title":"J. Health Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40259-017-0244-3","article-title":"Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists","volume":"31","author":"van Overbeeke","year":"2017","journal-title":"BioDrugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/ph14020117","article-title":"Informing Patients about Biosimilar Medicines: The Role of European Patient Associations","volume":"14","author":"Vandenplas","year":"","journal-title":"Pharmaceuticals (Basel)"},{"key":"B38","volume-title":"Probleemstelling en voorstellen tot maatregelen voor af-patent biologische en biosimilaire geneesmiddelen in Belgi\u00eb","author":"Vandenplas","year":"2020"},{"key":"B39","doi-asserted-by":"publisher","first-page":"644187","DOI":"10.3389\/fphar.2021.644187","article-title":"Off-patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis","volume":"12","author":"Vandenplas","year":"","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40259-019-00388-9","article-title":"Delivering on the Promise of Biosimilars","volume":"33","author":"Vulto","year":"2019","journal-title":"BioDrugs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/PPA.S129333","article-title":"Assessing Physician and Patient Acceptance of Infliximab Biosimilars in Rheumatoid Arthritis, Ankylosing Spondyloarthritis and Psoriatic Arthritis across Germany","volume":"11","author":"Waller","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"B42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/ph14040352","article-title":"The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition","volume":"14","author":"Wilder","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B43","first-page":"1","volume-title":"Overzicht Patentverloop Dure Geneesmiddelen","year":"2020"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.789640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T08:05:33Z","timestamp":1641369933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.789640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":43,"alternative-id":["10.3389\/fphar.2021.789640"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.789640","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"article-number":"789640"}}